Results 151 to 160 of about 18,669 (233)

Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B. [PDF]

Glob Reg Health Technol Assess, 2020
Aiello A, Mancuso ME, Colombo A, Teruzzi C, Berto P.   +4 more
europepmc   +1 more source

Peripheral Seal Composite Barrier (PSCB) for Management of Palatal Donor Sites in Mucogingival Surgery: A Randomized Clinical Trial

Clinical and Experimental Dental Research, Volume 12, Issue 5, October 2026.
ABSTRACT Objectives Management of the palatal donor site following periodontal plastic surgery remains challenging because of postoperative pain, bleeding, and patient discomfort. This study aimed to evaluate the efficacy of a chairside‐fabricated composite barrier in reducing morbidity at the palatal donor site.
Moein Khojaste, Farid Shiezadeh, Zahra Moslehitabar   +2 more
wiley   +1 more source

Adherence and Quality of Life in Adult Patients With Haemophilia A, Haemophilia B and Von Willebrand Disease: A National Cross-Sectional Survey. [PDF]

Eur J Haematol
Clausen CML, Funding E, Tolver A, Jarden M.   +3 more
europepmc   +1 more source

Factor VIII inhibitors demonstrate type I or type II kinetics in high‐titre alloantibodies and autoantibodies

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
The inhibitor kinetics type cannot be used by itself to determine auto‐ versus allo‐anti‐FVIII antibody type. To characterise inhibitor kinetics in inherited haemophilia A (HA) and acquired haemophilia A (AHA) patients in our centre, results show that inhibitors for both HA alloantibodies and AHA autoantibodies may exhibit either type I or type II ...
Cuicui Qiao, Jie Wang, Tiantian Wang, Hehe Wang, Yingfang Pan, Wei Liu, Yan Cheng, Feng Xue, Man‐Chiu Poon, Xinsheng Zhang, Yunhai Fang   +10 more
wiley   +1 more source

Teaching Cell and Gene Therapy in Genetic Counseling Programs: Survey Findings and Suggested Practical Resources for Integration

Journal of Genetic Counseling, Volume 35, Issue 5, October 2026.
ABSTRACT As cell and gene therapies (CGTs) advance through clinical trials into clinical practice, it becomes increasingly important for genetic counselors (GCs) to understand these therapeutics to discuss them with patients. Despite the apparent need for GCs to obtain CGT‐related education, little is known about the training GCs receive on CGT topics ...
Mariel Sebby, Lily McConachie, Leah Wetherill, Paula Delk, Emily L. Hopewell   +4 more
wiley   +1 more source

Haemophilia A and haemophilia B: molecular insights (corrected version). [PDF]

Molecular Pathology, 2002
openaire   +1 more source

Significant PK variability of plasma-derived FIX concentrates in chinese children with Haemophilia B: A fixed single-dose study of factor IX-CTBB. [PDF]

Glob Med Genet
Liu G, Ai D, Li G, Zhen Y, Wu X, Yao W, Wei Y, Li Z, Zhou Y, Wu R, Chen Z.   +10 more
europepmc   +1 more source

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies

British Journal of Haematology, Volume 209, Issue 4, Page 1469-1481, October 2026.
Gene therapy is revolutionizing treatment paradigms for haemoglobinopathies, establishing a translational framework for disorders that impact red blood cell development. In their paper, Joshi et al. describe the preclinical and early clinical landscape of gene therapies for non‐haemoglobinopathy erythroid disorders and highlight common thematic ...
Gaurav Joshi, Nandakumar Natarajan, Kathryn E. Dickerson, Richard A. Voit   +3 more
wiley   +1 more source

An Automated Microfluidic System for Haemostasis Assessment in Cirrhosis With Thrombocytopenia

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background & Aims Conventional laboratory tests do not capture platelet–vessel wall interactions (primary haemostasis) occurring in vivo, limiting guidance before invasive procedures. This is relevant in patients with thrombocytopenia, hallmark of advanced cirrhosis. Microfluidic assays may overcome these limitations.
Niccolò Bitto, Giulia Tosetti, Armando Tripodi, Anna Lecchi, Silvia La Marca, Lidia Padovan, Erica Scalambrino, Marigrazia Clerici, Camilla Caputo, Martina Lucà, Massimo Primignani, Anna Ludovica Fracanzani, Pietro Lampertico, Flora Peyvandi, Vincenzo La Mura   +14 more
wiley   +1 more source

Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors. [PDF]

Adv Ther
Pochopien M, Tytuła A, Toumi M, Falk A, Martone N, Hakimi Z, Eriksson D.   +6 more
europepmc   +1 more source